SPECTRUM RECEIVES NOTICE OF A PATENT ALLOWANCE FOR EOQUIN

Spectrum Pharmaceuticals has received a notice of allowance from the U.S. Patent and Trademark Office for its patent application for EOquin titled, "Medical Compositions for Intravesical Treatment of Bladder Cancer."

This patent, when issued, protects EOquin for use in the treatment of superficial bladder cancer and will not expire until November 2022.